Company Profile
An Ireland-based specialty biopharmaceutical company that makes Epidiolex — the world's first FDA-approved cannabis-derived prescription medicine — alongside a broader CNS, sleep, and oncology drug portfolio.
Rank #1
JAZZ
$243.47
-1.64% (24h)
Last updated: 1 second ago
Market Cap
$15.29B
Volume (24h)
671.74K
Last Close (7D)
$243.47
An Ireland-based specialty biopharmaceutical company that makes Epidiolex — the world's first FDA-approved cannabis-derived prescription medicine — alongside a broader CNS, sleep, and oncology drug portfolio.
Yahoo · 16h ago
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026
Benzinga · Jul 20, 2026
Global Payments To Rally More Than 28%? Here Are 10 Top Analyst Forecasts For Monday
Benzinga · Jul 20, 2026
Needham Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $282
SeekingAlpha · Jul 19, 2026
Stoke Therapeutics: Its Dravet Syndrome Lead Asset Enters The Last Stretch
Yahoo · Jul 18, 2026
Jazz Pharmaceuticals (JAZZ) Stock Still Looks Like A Bargain After A 119% Run
Yahoo · Jul 18, 2026
Jazz Pharmaceuticals (JAZZ) Refocuses Its Sleep Franchise, Is The Stock Still Cheap?
52-Week Range